Physician profile
Daniel Ryan Champey
NPI 1700836681
$1,944.33
in general payments reported to CMS, 2019-2025
26 companies · $43.91 in 2025
The $43.91 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $407 · 2021: $145 · 2022: $145 · 2023: $86.28 · 2024: $156 · 2025: $43.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $175 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.09 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $412.52 | 2019-2023 | |
| Ucb, INC. | $199.75 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $160.98 | 2019-2024 | |
| Genzyme Corporation | $150.99 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $147.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $125.17 | 2020-2022 | |
| Emd Serono, INC. | $120.56 | 2019-2020 | |
| Amgen INC. | $118.25 | 2019-2020 | |
| Abbott Laboratories | $51.93 | 2021-2025 | Infinity |
| Avanir Pharmaceuticals, INC. | $50.95 | 2019 | |
| Alexion Pharmaceuticals, INC. | $48.92 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $46.47 | 2022 | |
| Livanova USA, INC. | $43.71 | 2019-2022 | |
| Genentech USA, INC. | $41.71 | 2023-2024 | Ocrevus, Ocrevus Zunovo |
| Daiichi Sankyo INC. | $31.73 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $31.61 | 2023-2024 | |
| Medtronic, INC. | $31.25 | 2022-2023 | Intellis Adaptivestim |
| Abbvie INC. | $20.63 | 2025 | |
| Corium, LLC | $16.08 | 2022 | |
| Adamas Pharmaceuticals, INC. | $15.25 | 2020 | |
| Celgene Corporation | $13.64 | 2023 | Zeposia |
| Acadia Pharmaceuticals INC | $13.61 | 2019 | |
| Boston Scientific Corporation | $13.48 | 2019 | |
| Kyowa Kirin, INC. | $13.22 | 2019 | |
| Biogen, INC. | $12.93 | 2023 | Vumerity |
| Arbor Pharmaceuticals, INC. | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Champey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.